The T-Body™ Platform Three targets, one IgG-like antibody

The T-Body™ platform puts three binding arms on a single IgG-like antibody, so you can engage three targets at once. It uses novel constant-domain engineering strategies and was built by the same team that brought you the B-Body platform. The result is a trispecific you can express and purify like a monoclonal antibody. T-Body trispecific antibodies unlock new mechanisms of action, enabling development of significantly more advanced therapeutics.

Jump to the details

1.5

g/L from transient expression

>0%

Typical final purity

κ + λ

Compatible with kappa and lambda light chains

Unique trispecific constructs made

The Problem Engineering trispecific antibodies is harder than just adding another binder

A bispecific antibody without proper engineering can have four chains that pair the wrong way, leading to project failure. Add a third unique binding arm to the mix and complexity and failure rate dramatically rise. Most trispecific platforms get around this by either using non-IgG-like formats or identifying custom engineering solutions, all of which increase risk, cost, and time.

Stepping away from an IgG-like solution increases the risk of losing the long half-life, manufacturability and developability advantages that come with Fab-based engineering solutions. T-Body keeps the IgG-like structure and solves assembly with a platform solution that eliminates the need for custom engineering.

Fc Region

Knobs-into-holes Fc

Drives heavy chain heterodimerization. Clinically validated.

One heavy chain has a "knob" mutation, the other a "hole"
They preferentially pair with each other, not with themselves
Compatible with standard Fc substitutions for effector engineering

FAB Arms

Proprietary CH3 domain pairs

The central innovation that solves light chain mispairing.

CH1/CL is replaced with proprietary CH3 mutations in the Fab arms
Forces the correct heavy-light chain pairing on its own
No common light chain required, no variable domain engineering

HEAVY & LIGHT CHAINS

Symmetrical chain inversions

Makes variable domains plug-and-play.

Proprietary symmetrical arrangement of heavy and light chains in the Fab arms
Accepts variable domains from any source without re-engineering
Robust expression yields and efficient purification

SOLE CH1 DOMAIN

One-step purification

Anti-CH1 affinity capture beyond Protein A and IEX.

Only one Fab arm carries a CH1 domain
Anti-CH1 resin captures correctly assembled trispecifics in a single step
Removes homodimers and other impurities, simplifies in-format discovery

Roland Green CEO and Founder, Invenra

The T-Body™ platform was born out of the desire to bring more weapons to bear in the fight against cancer. Tumors can be wily opponents with many escape routes. Having a third targeting arm gives us a better chance of outmaneuvering the tumor and providing a more efficacious and durable treatment for patients”.

Validated performance Strong expression, binding, and performance

Rapid Prototyping with Challenging Antibodies

The platform was stress-tested with four clinical antibodies chosen for difficult developability (Jain et al., PNAS 2017), three kappa and one lambda. Every arrangement of their domains makes 24 different T-Bodies, and the platform handled the whole set.

4 challenging clinical antibodies: PD-L1, CD25, TNFα, IL23 (3 kappa, 1 lambda)
All domain arrangements make 24 T-Bodies
Expi-CHO expression, one-step CH1 purification
75–95% purity by non-reducing CE-SDS

Matrix Analysis of T-Body Performance Expression Results from a matrix of clinical antibodies (top table) in the T-Body Platform are shown, bottom. Expi-CHO expression followed by one-step CH1 purification resulted in 75–95% purity by non-reducing CE-SDS

Robust Expression & Purity

up to 1.5 g/L

T-Body trispecifics express well in standard HEK and CHO systems and come off a single CH1 affinity step as well-resolved material. Mass spec confirms the molecule assembled the way it should.

Expression in HEK and CHO is typically up to 1.5 g/L
Single-step purification on CH1 resin, with up to 95% purity
Well-resolved SEC and SMAC chromatograms, low misassembly
LC-MS confirms correct assembly of the purified molecule

96% pure by SEC after second step purification
A representative chromatogram showing purity of T-Body trispecific after second step purification.

Non-reducing and reducing CE images of purified T-Body trispecific
A representative capillary electropherogram showing purity of T-Body trispecific after second step purification.

T-Body Binding Kinetics

3 targets

Each arm is measured on its own. Binding to all three targets is assessed by BLI and SPR, and the trispecific’s kinetics line up with single-arm controls for every target. Both kappa and lambda arms perform well.

Simultaneous binding to three distinct antigens (Target A, B, C)
Measured by biolayer interferometry (BLI) and SPR
Each Fab arm’s kinetics assessed independently (ka, kd, KD)
Trispecific kinetics match one-armed controls, for kappa and lambda

Assessing T-Body Trispecific Binding Kinetics (Top/Right) Antigen binding of Target A, Target B, and Target C. (Bottom) Comparable binding & kinetics between the trispecific antibody and the corresponding one-armed control, with good performance for both kappa and lambda antibodies

Manufacturing & CMC T-Body antibodies are designed to manufacture like monoclonal antibodies

CAPTURE

Protein A or anti-CH1

Standard Protein A, or single-step anti-CH1 for one-pass purity.

POLISH

Ion exchange

Conventional polishing, the same as a monoclonal.

CONFIRM

SEC + CE-SDS

Low aggregate formation, well-resolved material.

Compatibility The T-Body platform adapts to your needs

Three Fab arms

Three binding domains on one IgG-like antibody, engaging three antigens at once for receptor clustering, target specificity, and new immunomodulatory mechanisms.

κλ

Kappa and lambda light chains

Both light chain classes work across the Fab arms. The 24-construct matrix included three kappa and one lambda antibody.

VH/VL

Multiple trispecific formats

Multiple architectures supported. The same scaffold accommodates trivalent and tetravalent designs.

IgG-like structure

Keeps the Fc and a real antibody shape, so the molecule holds a true IgG half-life instead of the short exposure typical of fusion formats.

ADC

ADC conjugation

The format supports payload conjugation. Invenra has shown trispecific ADCs that kill tumor cells across HER2-high, HER2-low, and triple-negative breast cancer lines.

Conventional CMC infrastructure

Designed to work with conventional CMC processes.

HOW TO WORK WITH US How to access the platform

Most teams come to the T-Body platform through a discovery program. For deeper, longer-term work, we structure custom partnerships and licenses.

Full discovery

T-Body Discovery

A custom trispecific discovery program built around your three targets and your target product profile. You bring the biology and the strategy. We run the discovery on the platform.

Explore T-Body Discovery

PARTNERSHIP & LICENSING No two trispecific programs are the same

T-Body is a novel, premium platform, and the relationships around it are strategic and collaborative. So instead of a fixed menu, we offer a range of licensing structures built around your program.

Shared risk, shared reward. Through co-discovery options, back-loaded payments, and performance-based milestones, we line up our interests with yours from preclinical work through commercialization.

Adapted to your needs. A project can fit your timeline, therapeutic area, budget, risk tolerance, and commercial goals.

Learn more about licensing »

Co-discovery options

Build the program together from the start

Back-loaded payments

Weight the cost toward later, de-risked stages

Performance-based milestones

Tied to progress from preclinical to commercial

Frequently Asked Questions Quick answers to initial questions

How is a T-Body different from a bispecific?

It binds three targets instead of two. We use similar constant-domain engineering strategy as the B-Body platform, extended to a third Fab arm, all in one IgG-like antibody.

Is it really IgG-like, or a fusion format?

It’s IgG-like. Three Fab arms sit on a single antibody with an Fc, not a fusion of fragments, so it keeps a real antibody’s half-life and manufacturability.

How do the chains pair correctly with three arms?

The engineering sits in the constant domains. Proprietary CH3 domain pairs replace CH1/CL in the Fab arms, so the right chains pair on their own. No common light chain needed.

Does it work with kappa and lambda?

Yes, both, across the Fab arms. The 24-construct matrix included three kappa and one lambda antibody.

What antibody sources work?

Variable domains from any source. The platform was validated on clinical antibodies chosen for difficult developability, not cherry-picked easy ones.

Can I make a trispecific ADC?

Yes, absolutely. The format supports payload conjugation, and Invenra has shown trispecific ADCs that kill tumor cells across HER2-high, HER2-low, and triple-negative breast cancer lines.

Will my CDMO need special equipment?

No. It’s a human IgG, so it runs on Protein A, ion exchange, and standard polishing, with an anti-CH1 one-step option.

How do I access the platform?

Through a T-Body Discovery program or a custom partnership and license. Because T-Body is a premium platform, engagements are structured program by program.

Get in touch Talk to us about hitting three targets

Tell us about your targets and what success looks like, and we’ll map out a path on the T-Body platform.

Your information is 100% confidential.

We don't share your data with third parties, add you to marketing lists without permission, or contact you about anything other than this request. Target biology is treated as confidential. Need an NDA first? Just say so. We'll send one over.